Long-term efficacy and tolerability of add-on pramipexole for anhedonic depression – an open label follow-up study

Conditions

Depression

Brief summary

Total SHAPS-C scores

Detailed description

HDRS6 scores, Number of steps/day, movement pattern distribution over the day, walking distance, time spent in light, moderate and intense physical activity, resting heart rate, blood oxygen saturation, heart rate variability (stress scores), sleep latency (time to fall asleep), sleep awakening (how often you wake up during the night), wakefulness (time in minutes awake during a night), time in deep sleep, sleep efficiency (time asleep vs. total time in bed)., Total scores of DARS, MADRS-S, Insomnia Severity Scale, AES, GAD-7 and BBQ., Adverse events and side effects, fMRI, blood and CSF biomarkers from the RCT as treatment predictors., Neuropsychological test battery consisting of WAIS-IV, RBANS, D-KEFS, CPT-3 and cognitive self-assessment PDQ-5.

Related papers

No related papers found yet.

Interventions

DRUGPRAMIPEXOLE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Total SHAPS-C scores	—

Secondary

Measure	Time frame
HDRS6 scores, Number of steps/day, movement pattern distribution over the day, walking distance, time spent in light, moderate and intense physical activity, resting heart rate, blood oxygen saturation, heart rate variability (stress scores), sleep latency (time to fall asleep), sleep awakening (how often you wake up during the night), wakefulness (time in minutes awake during a night), time in deep sleep, sleep efficiency (time asleep vs. total time in bed)., Total scores of DARS, MADRS-S, Insomnia Severity Scale, AES, GAD-7 and BBQ., Adverse events and side effects, fMRI, blood and CSF biomarkers from the RCT as treatment predictors., Neuropsychological test battery consisting of WAIS-IV, RBANS, D-KEFS, CPT-3 and cognitive self-assessment PDQ-5.	—

Measure

Time frame

HDRS6 scores, Number of steps/day, movement pattern distribution over the day, walking distance, time spent in light, moderate and intense physical activity, resting heart rate, blood oxygen saturation, heart rate variability (stress scores), sleep latency (time to fall asleep), sleep awakening (how often you wake up during the night), wakefulness (time in minutes awake during a night), time in deep sleep, sleep efficiency (time asleep vs. total time in bed)., Total scores of DARS, MADRS-S, Insomnia Severity Scale, AES, GAD-7 and BBQ., Adverse events and side effects, fMRI, blood and CSF biomarkers from the RCT as treatment predictors., Neuropsychological test battery consisting of WAIS-IV, RBANS, D-KEFS, CPT-3 and cognitive self-assessment PDQ-5.

—

Countries

Sweden

Outcome results

None listed